North America Pharmaceutical Excipients Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
|
 Market Size (Forecast Year) |
USD 6,894.31 |
 CAGR |
% |
| Major Markets Players |
北美药用辅料市场，按功能（粘合剂和胶粘剂、崩解剂、涂层材料、崩解剂、增溶剂、调味剂、甜味剂、稀释剂、润滑剂、缓冲剂、乳化剂、防腐剂、抗氧化剂、吸附剂、溶剂、润肤剂、助流剂、螯合剂、消泡剂等）、剂型（固体、半固体、液体）、给药途径（口服辅料、外用辅料、肠外辅料、其他辅料）、最终用户（制药和生物制药公司、合同配方师、研究组织和学者等）、按分销渠道（直接招标、零售销售等）划分 - 行业趋势和预测到 2030 年。
北美药用辅料市场分析与洞察
药用辅料在药物配方和开发中起着重要作用。这些物质包括除药理活性药物或前体药物以外的物质。药用辅料可有效地将药物输送到目标部位。这些分子可防止药物在吸收过程中过早释放并增强药物功效。一些药用辅料可促进药物整合，从而促进药物在血液中的吸收。
Data Bridge Market Research 分析，北美药用辅料市场预计到 2030 年将达到 68.9431 亿美元的价值，预测期内的复合年增长率为 6.6%。由于北美对 IT 解决方案和服务的需求迅速增长，功能性辅料占据了市场中最大的类型细分市场。本市场报告还深入介绍了定价分析、专利分析和技术进步。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
按功能（粘合剂和胶粘剂、崩解剂、包衣材料、崩解剂、增溶剂、调味剂、甜味剂、稀释剂、润滑剂、缓冲剂、乳化剂、防腐剂、抗氧化剂、吸附剂、溶剂、润肤剂、助流剂、螯合剂、消泡剂等）、剂型（固体、半固体、液体）、给药途径（口服辅料、外用辅料、肠外辅料、其他辅料）、最终用户（制药和生物制药公司、合同配方师、研究机构和学者等）、按分销渠道（直接招标、零售、其他） |
|
覆盖国家 |
美国、加拿大、墨西哥 |
|
涵盖的市场参与者 |
Kerry Group plc.、DFE Pharma、Cargill, Incorporated、Pfanstiehl、Colorcon、MEGGLE GmbH & Co. KG、Omya AG、Peter Greven GmbH & Co. KG、Ashland.、Evonik、Dow、Croda International Plc、Roquette Frères.、The Lubrizol Corporation、BASF SE、Avantor, Inc.、BENEO 等 |
北美药用辅料市场定义
药用辅料包括药物中除活性药物成分以外的所有成分。这些分子不具有药用特性，最终用于增强药物的生理吸收。药用辅料是惰性的，可使药物分子以正确的形式应用于患者。传统上，药用辅料是简单的分子，但技术创新和对新型药物输送系统日益增长的需求增加了药用辅料的复杂性。药用辅料可提高患者对药物的接受度，并提高药物的稳定性和生物利用度。
辅料科学技术的未来已经改变并将继续改变。在协调辅料药典专论和应用新分析方法更好地表征辅料等方面取得了更好的进展。
北美药用辅料市场动态
本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：
驱动程序
- 仿制药生产和使用的增加
根据美国食品药品管理局（FDA）和美国国家生物技术信息中心（NCBI）的定义，仿制药是一种被制造成看起来像已获批准的品牌药的药物，该药物的剂型、安全性、强度、给药途径、质量和性能都与品牌药相似。在药物专利到期后，与传统药物使用相关的成本节省不会立即显现出来。仿制药和品牌药一样，需要仿制药市场的竞争才能降低成本；在失去独占权两到三年后，仿制药的价格通常比品牌药低60-70%。由于印度的人均支出最高，这些仿制药将节省大量资金，这些资金可用于其他健康问题。在全国范围内，近年来仿制药的使用量显着增加。品牌药的廉价替代品是刺激制药行业增长的主要原因。仿制药行业在不久的将来会蓬勃发展。
因此，仿制药需求的增加和产量的上升预计将推动北美药用辅料市场的增长。此外，仿制药的成本较低，这增加了仿制药的使用。
- 辅料需求激增
药用辅料是药物剂型中不直接用于治疗用途，而是用于促进制造、保护、支持或改善稳定性和可用性的物质。随着北美制药业的不断发展，辅料也占有一席之地。最近，仿制药的需求不断增加，这导致辅料需求增加。此外，慢性病病例急剧增加。
辅料是除药用活性药物之外的惰性物质，被引入到制造过程中或包含在药品剂型中。辅料广泛用于药物配方中，以增加固体制剂的体积、提供长期稳定性并促进药物吸收。此外，它还可以提高产品在使用或储存过程中的整体安全性或功能特性。
因此，辅料在药物配方中的广泛使用和辅料的应用有望推动北美药用辅料市场的发展。
克制
- 药品和辅料审批监管趋严
仿制药审批规则在世界各地大致相同，发展中国家差别不大。这是因为在发展中国家，仿制药审批不需要进行生物等效性 (BE) 研究。医学专家表示，政府必须确保所有仿制药的质量始终如一。只有这样，医生才会乐意和自信地开出仿制药。医生（甚至患者）对仿制药缺乏信心的一个主要原因是，对仿制药数量和允许的杂质数量缺乏严格的监管要求。
控制辅料的生产和分销现在被监管机构和药品制造商视为首要任务，因为混合辅料会导致患者出现不良反应。此外，随着新辅料和输送系统的出现，在体内活动的背景下，更好地控制药用辅料的质量和供应变得越来越重要。认识到辅料在药物剂型中的重要作用，需要辅料供应商满足制药行业的质量要求，而制药行业总体上必须努力确保产品的安全性。供应链中使用或存储的完整性。因此，预计药品和辅料审批监管日益严格将抑制北美药用辅料市场的增长。
机会
-
市场参与者的战略举措
药用辅料市场的崛起增加了对战略性商业理念的需求。它包括合作伙伴关系、业务扩张和其他发展。对药品的需求不断增长，大大增加了对药用辅料的需求，为了满足这种需求，公司正在建设新的生产基地，以及其他战略举措。
这些战略举措，例如主要市场参与者的产品发布、收购、协议和业务扩展，将促进药用辅料市场的增长，并有望为北美药用辅料市场带来机遇。
挑战
- 相关副作用
药物制剂中的药用辅料引起的不良反应通常并不常见，但高剂量（毫克/千克）会增加毒性，尤其是对新生儿和婴儿。甲基和丙基对羟基苯甲酸酯（对羟基苯甲酸酯）、苯甲醇、苯甲酸钠、苯甲酸和丙二醇等是一些已报告副作用的常见药用辅料。
药用辅料并不总是我们所认为的惰性物质。它们对某些人而言是无法耐受的，或者如果未经过适当筛选，可能会导致药物发生化学变化，从而产生副作用。这可能会影响对辅料的需求，预计会给北美药用辅料市场带来挑战。
后 COVID-19 对北美药用辅料市场的影响
制药行业受到 COVID-19 疫情的严重影响。因疫情而实施的封锁中断了印度和中国等制造中心的原材料供应。这减缓了药物开发和生产，严重影响了严重依赖外包的公司。最初，整个制药生态系统被打乱。此外，监管机构不得不起草和制定新法律，以确保患者在使用药物后获得最大程度的安全。封锁结束后，制药行业获得了动力，尤其是由于对羟氯喹和瑞德西韦等药物的需求，这些药物在对抗 COVID-19 方面显示出了积极效果。对这些药物不断增长的需求推动了一些公司的营业额。
制造商正在制定各种战略决策，以在新冠疫情后实现复苏。参与者正在进行多项研发活动、产品发布和战略合作，以改进药用辅料市场的技术。
最新动态
- 2022 年 2 月，全球领先的口味和营养公司 Kerry Group Plc. 宣布已进行两项重大生物技术收购，扩大了其专业知识、技术组合和制造能力。该公司宣布已收购领先的生物技术创新公司 c-LEcta 和墨西哥酶制造商 Enmex。c-LEcta 是一家领先的生物技术创新公司，专门从事精密发酵、优化生物加工和生物转化。此外，Enmex 是一家总部位于墨西哥的知名酶制造商，为食品、饮料和动物营养市场提供多种生物工艺解决方案。这有助于该公司增加收入
- 2022 年 9 月，北美领先的制药和营养辅料解决方案提供商 DFE Pharma 在印度海得拉巴开设了新的卓越中心“Closer to the Formulator”（C2F）。C2F 通过其在药物开发各个阶段的专业知识，帮助制药公司缩短从概念到成品的时间。这有助于该公司展示其进步
北美药用辅料市场范围
北美药用辅料市场细分为功能、剂型、给药途径、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
北美药用辅料市场，按功能划分
- 粘合剂和胶粘剂
- 崩解剂
- 涂层材料
- 着色剂
- 增溶剂
- 口味
- 甜味剂
- 稀释剂
- 润滑剂
- 缓冲区
- 乳化剂
- 防腐剂
- 抗氧化剂
- 吸附剂
- 溶剂
- 润肤剂
- 滑行器
- 螯合剂
- 消泡剂
- 其他的
根据功能，北美药用辅料市场分为粘合剂和胶粘剂、崩解剂、包衣材料、着色剂、增溶剂、调味剂、甜味剂、稀释剂、润滑剂、缓冲剂、乳化剂、防腐剂、抗氧化剂、吸附剂、溶剂、润肤剂、助流剂、螯合剂、消泡剂等。
北美药用辅料市场（按剂型划分）
- 坚硬的
- 半固体
- 液体
根据剂型，北美药用辅料市场分为固体、半固体和液体
北美药用辅料市场（按给药途径划分）
- 口服辅料
- 外用辅料
- 肠外辅料
- 其他药用辅料
根据给药途径，北美药用辅料市场分为口服药用辅料、外用药用辅料、肠外药用辅料和其他药用辅料。
北美药用辅料市场，按最终用户划分
- 制药和生物制药公司
- 合同配方师
- 研究机构和学者
- 其他的
根据最终用户，北美药用辅料市场分为制药和生物制药公司、合同配方商、研究机构和学术机构等
北美药用辅料市场，按分销渠道划分
- 直接招标
- 零售销售
- 其他的
根据分销渠道，北美药用辅料市场分为直接招标、零售和其他。
北美药用辅料市场区域分析/见解
对北美药用辅料市场进行了分析，并提供了功能、剂型、给药途径、最终用户和分销渠道的市场规模信息。
本市场报告涵盖的国家包括美国、加拿大和墨西哥。
北美占据主导地位，因为其最大的消费市场拥有主要市场参与者，且 GDP 较高。由于医疗 IT 技术进步的提升，美国预计将实现增长。
北美占据市场主导地位。研发投资的增加预计将推动市场增长。由于 Evonik、Dow、Croda International Plc 等主要参与者的强大影响力，美国在北美地区占据主导地位。由于药品的大规模生产、新兴市场需求的增加以及医疗保健行业的扩张，英国在欧洲占据主导地位。由于医药市场的快速增长以及仿制药产量的增加，中国在亚太地区占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响。
竞争格局和北美药用辅料市场份额分析
北美药用辅料市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对北美药用辅料市场的关注有关。
北美药用辅料市场的一些主要参与者包括 Kerry Group plc.、DFE Pharma、Cargill, Incorporated、Pfanstiehl、Colorcon、MEGGLE GmbH & Co. KG、Omya AG、Peter Greven GmbH & Co. KG、Ashland.、Evonik、Dow、Croda International Plc、Roquette Frères.、The Lubrizol Corporation、BASF SE、Avantor, Inc.、BENEO 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 FUNCTIONALITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 INDUSTRIAL INSIGHTS:
5 NORTH AMERICA PHARMACEUTICAL EXCIPIENT MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN GENERIC DRUG PRODUCTION AND USES
6.1.2 THE SURGE IN DEMAND FOR EXCIPIENTS
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN MULTIFUNCTIONAL EXCIPIENTS
6.1.4 RISING FOCUS ON ORPHAN DRUGS
6.2 RESTRAINTS
6.2.1 INCREASING REGULATORY STRINGENCY REGARDING THE APPROVAL OF DRUGS AND EXCIPIENTS
6.2.2 HIGH PRODUCTION COST
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
6.3.2 RISING DEMAND FOR EASE OF USE
6.3.3 RISING DISPOSABLE INCOME
6.3.4 INCREASING DEMAND FOR ALTERNATIVE ROUTES OF DELIVERY/DOSAGE FORMS
6.4 CHALLENGES
6.4.1 ASSOCIATED SIDE EFFECTS
6.4.2 SAFETY CONSIDERATION OF PHARMACEUTICAL EXCIPIENTS IN STORAGE & TRANSPORTATION
6.4.3 LACK OF NOVEL PHARMACEUTICAL EXCIPIENTS
7 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY
7.1 OVERVIEW
7.2 BINDERS AND ADHESIVES
7.2.1 ORGANIC
7.2.2 INORGANIC
7.3 DISINTEGRANTS
7.3.1 ORGANIC
7.3.2 INORGANIC
7.4 COATING MATERIAL
7.4.1 ORGANIC
7.4.2 INORGANIC
7.5 COLORING AGENTS
7.5.1 ORGANIC
7.5.2 INORGANIC
7.6 SOLUBILIZERS
7.6.1 ORGANIC
7.6.2 INORGANIC
7.7 FLAVORS
7.7.1 ORGANIC
7.7.2 INORGANIC
7.8 SWEETENING AGENTS
7.8.1 ORGANIC
7.8.2 INORGANIC
7.9 DILUENTS
7.9.1 ORGANIC
7.9.2 INORGANIC
7.1 LUBRICANTS
7.10.1 ORGANIC
7.10.2 INORGANIC
7.11 BUFFERS
7.11.1 ORGANIC
7.11.2 INORGANIC
7.12 EMULSIFYING AGENTS
7.12.1 ORGANIC
7.12.2 INORGANIC
7.13 PRESERVATIVES
7.13.1 ORGANIC
7.13.2 INORGANIC
7.14 ANTIOXIDANTS
7.14.1 ORGANIC
7.14.2 INORGANIC
7.15 SORBENTS
7.15.1 ORGANIC
7.15.2 INORGANIC
7.16 SOLVENTS
7.16.1 ORGANIC
7.16.2 INORGANIC
7.17 EMOLLIENTS
7.17.1 ORGANIC
7.17.2 INORGANIC
7.18 GLIDENTS
7.18.1 ORGANIC
7.18.2 INORGANIC
7.19 CHELATING AGENTS
7.19.1 ORGANIC
7.19.2 INORGANIC
7.2 ANTIFOAMING AGENTS
7.20.1 ORGANIC
7.20.2 INORGANIC
7.21 OTHERS
8 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM
8.1 OVERVIEW
8.2 SOLID
8.2.1 PLANT
8.2.2 ANIMALS
8.2.3 SYNTHETIC
8.2.4 MINERALS
8.3 SEMI-SOLID
8.3.1 PLANT
8.3.2 ANIMALS
8.3.3 SYNTHETIC
8.3.4 MINERALS
8.4 LIQUID
8.4.1 PLANT
8.4.2 ANIMALS
8.4.3 SYNTHETIC
8.4.4 MINERALS
9 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL EXCIPIENTS
9.3 TOPICAL EXCIPIENTS
9.4 PARENTERAL EXCIPIENTS
9.5 OTHER EXCIPIENTS
10 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT TENDER
10.2.1 COMPANY TENDER
10.2.2 TENDER THROUGH MARCH MERCHANDISER
10.3 RETAIL SALES
10.4 OTHERS
11 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END USER
11.1 OVERVIEW
11.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
11.3 CONTRACT FORMULATORS
11.4 RESEARCH ORGANIZATION
11.5 OTHERS
12 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION
12.1 U.S.
12.2 CANADA
12.3 MEXICO
13 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 DOW
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 ROQUETTE FRÈRES.
15.2.1 COMPANY SNAPSHOT
15.2.2 COMPANY SHARE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 EVONIK
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 THE LUBRIZOL CORPORATION
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.5 BASF SE
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.6 ASHLAND (2021)
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.7 AVANTOR, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 BENEO
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 CARGILL, INCORPORATED.
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 COLORCON
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 CRODA INTERNATIONAL PLC
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENTS
15.12 DFE PHARMA (SUBSIDIARY OF ROYAL FRIESLANDCAMPINA N.V)
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 KERRY GROUP PLC.
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 MEGGLE GMBH & CO. KG
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 OMYA AG
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
15.16 PETER GREVEN GMBH & CO. KG
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 PFANSTIEHL
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 2 NORTH AMERICA BINDERS AND ADHESIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 3 NORTH AMERICA DISINTEGRANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 4 NORTH AMERICA COATING MATERIAL IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 5 NORTH AMERICA COLORING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 6 NORTH AMERICA SOLUBILIZERS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 7 NORTH AMERICA FLAVORS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 8 NORTH AMERICA SWEETENING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 9 NORTH AMERICA DILUENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 10 NORTH AMERICA LUBRICANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 11 NORTH AMERICA BUFFERS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 12 NORTH AMERICA EMULSIFYING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 13 NORTH AMERICA PRESERVATIVES IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 14 NORTH AMERICA ANTIOXIDANTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 15 NORTH AMERICA SORBENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 16 NORTH AMERICA SOLVENTS PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 17 NORTH AMERICA EMOLLIENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 18 NORTH AMERICA GLIDENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 19 NORTH AMERICA CHELATING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 20 NORTH AMERICA ANTIFOAMING AGENTS IN PHARMACEUTICAL EXCIPIENTS MARKET, FUNCTIONALITY, 2015-2029 (USD MILLION)
TABLE 21 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION)
TABLE 22 NORTH AMERICA SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION)
TABLE 23 NORTH AMERICA SEMI-SOLID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION)
TABLE 24 NORTH AMERICA LIQUID IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM, 2015-2029 (USD MILLION)
TABLE 25 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION, 2015-2029 (USD MILLION)
TABLE 26 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL, 2015-2029 (USD MILLION)
TABLE 27 NORTH AMERICA DIRECT TENDER IN PHARMACEUTICAL EXCIPIENTS MARKET, BY DISTRIBUTION CHANNEL, 2015-2029 (USD MILLION)
TABLE 28 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END USER, 2015-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: SEGMENTATION
FIGURE 12 THE RISE IN GENERIC DRUG PRODUCTION AND TECHNOLOGICAL FOCUS ON PHARMACEUTICAL EXCIPIENTS IS DRIVING THE NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE BINDERS AND ADHESIVES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET
FIGURE 15 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET : BY FUNCTIONALITY, 2021
FIGURE 16 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET : BY FUNCTIONALITY, 2022-2029 (USD MILLION)
FIGURE 17 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET : BY FUNCTIONALITY, CAGR (2022-2029)
FIGURE 18 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET : BY FUNCTIONALITY, LIFELINE CURVE
FIGURE 19 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DOSAGE FORM, 2021
FIGURE 20 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)
FIGURE 21 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 22 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 23 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 24 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 25 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 26 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 27 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 28 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 29 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 30 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 31 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET : BY END USER, 2021
FIGURE 32 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 34 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET : BY END USER, LIFELINE CURVE
FIGURE 35 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: SNAPSHOT (2021)
FIGURE 36 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY COUNTRY (2021)
FIGURE 37 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 38 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 39 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: BY FUNCTIONALITY (2022-2029)
FIGURE 40 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY SHARE 2021 (%)
FIGURE 41 NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
